Rozel 60mg Injection

Rozel 60mg Injection contains the active ingredient Denosumab and is used to treat osteoporosis, a condition where bones become weak and brittle. It is also prescribed to prevent bone complications in patients with certain types of cancer, such as multiple myeloma or bone metastases. The medication works by inhibiting a protein called RANK ligand, which is involved in the breakdown of bone tissue. Studies have shown that Rozel can significantly increase bone density and reduce the risk of fractures in postmenopausal women with osteoporosis and cancer-related bone loss.

Patients receiving Rozel should have their renal function monitored closely, especially if they have moderate renal impairment. It should not be used by individuals who have known hypersensitivity or allergic reactions to any of its components. Adequate calcium and vitamin D supplementation is necessary during treatment to support bone health.

Rozel 60mg Injection is not approved for use in children or adolescents, as its safety and effectiveness in pediatric populations have not been established. Additionally, caution should be exercised in patients with pre-existing hypoparathyroidism (low parathyroid hormone levels).